ESC 365 - Infection risk and management in VAD treatment - the weakest link?

HFA Premium Access

Infection risk and management in VAD treatment - the weakest link?

Session: Therapeutic dilemmas in patients with left ventricular assist device (LVAD)

Topic: Device Therapy

Speaker: Professor L. Van Laake (Utrecht, NL)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Professor Linda Van Laake

University Medical Center Utrecht, Utrecht (Netherlands (The))

25 presentations

6 followers

4 more presentations in this session

Dual or single anticoagulation/antiplatelet therapy in LVAD patients?

Speaker: Professor F. Bader (Abu Dhabi, AE)

The right ventricle - the Cinderella of LVAD treatment

Speaker: Professor M. Cikes (Zagreb, HR)

Future perspectives

Speaker: Professor M. Mehra (Boston, US)

Therapeutic dilemmas in patients with LVAD - discussion

Access the full session

Therapeutic dilemmas in patients with left ventricular assist device (LVAD)

Speakers: Professor L. Van Laake, Professor F. Bader, Professor M. Cikes, Professor M. Mehra

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources